Quanterix outlines $85M synergy target and signals 2026 cash flow breakeven as integration advances

Earnings Call Insights: Quanterix Corporation (QTRX) Q3 2025

MANAGEMENT VIEW

* Masoud Toloue, President and CEO, stated that "we're pleased with how we executed in the third quarter, especially given the significant integration work underway and the challenging industry conditions we continue to navigate." He highlighted delivery on revenue expectations, progress on integration following the Akoya acquisition, and realization of $67 million of the $85 million in targeted synergies. Toloue emphasized, "We're making significant investments in Alzheimer's diagnostics and in new assays across our Simoa and Spatial franchises. Year-to-date, we've invested roughly $27 million in R&D, just under 30% of our revenue, which underscores our conviction in the opportunities ahead and the innovation pipeline we're building." He also noted the company is "on track to finish the year with around $120 million in cash and no debt and will be cash flow breakeven in 2026."
* Vandana Sriram, CFO & Treasurer, stated, "Total revenue for Q3 was $40.2 million, an increase of 12% year-over-year. From a product perspective, Simoa contributed $23 million, a 36% organic revenue decline and Spatial reported $17.2 million, down 9% year-over-year." She also said, "We've tightened the gross margin ranges versus our prior guide as we know more about the effects of integrating Akoya, and these account for the allocation changes I touched upon earlier. None of the allocation changes impact our cash construct."

OUTLOOK

* Sriram reiterated full-year 2025 revenue guidance of $130 million to $135 million, with $100 million to $105 million of Simoa revenue and pro forma revenue of $165 million to $170 million if the two companies were combined for the full year. She added, "We expect GAAP gross margin to range between 45% and 47% and non-GAAP gross margin to be in the same range."
* Adjusted cash usage is expected to be $34 million to $38 million for the full year, with a projected year-end cash balance of approximately $120 million and no debt. Sriram noted, "The sequential cash improvements from $16 million of adjusted cash usage in Q3 is expected to come from incremental synergy realization in the quarter as well as working capital improvements."

FINANCIAL RESULTS

* The company reported $40.2 million in total revenue for Q3, with $23 million from Simoa and $17.2 million from Spatial. Instrument revenue was $7.2 million, consumable revenue was $18.8 million, and Accelerator lab revenue was $8 million. Diagnostics-related revenue was $2.4 million in the quarter.
* Gross profit and margin were $17.2 million and 42.8%, respectively. Non-GAAP gross profit was $18.5 million and non-GAAP gross margin was 45.9%.
* Operating expenses were $54.5 million, including $15 million of costs related to acquisition, integration, restructuring and purchase accounting. Adjusted EBITDA was a loss of $11.9 million.
* The company ended the quarter with $138 million in cash, cash equivalents, marketable securities and restricted cash after paying approximately $126 million in deal-related costs and acquiring $16.8 million in cash from Akoya.

Q&A

* Kyle Mikson, Canaccord Genuity Corp.: Asked about Simoa consumables decline. Toloue responded that "the order volume was consistent with last year, but the order size was smaller, which explained the entire decline... we're getting the same number of customers ordering the products, just project sizes is smaller than it was in the prior year."
* Mikson: Inquired about integration synergies. Toloue indicated that "we've already implemented the single manufacturing team and we're now combining lab services... as we enter at the beginning of next year, we'll have the company running on a single ERP with all systems and financials integrated into one organization."
* Mikson: Asked about diagnostics and reimbursement. Toloue replied that "we got the preliminary reimbursement recommendation... we do expect to gain some traction based on this pricing."
* Daniel Brennan, TD Cowen: Probed on Akoya business and Q4 assumptions. Sriram confirmed a "slight step down simply because there's a level of uncertainty in the market still."
* Brennan: Questioned commercial synergies and cross-selling. Toloue stated, "Early days, it's been positive... we have probably a double-digit list of opportunities that we're tracking and early days have been positive."
* Puneet Souda, Leerink Partners: Asked about the impact of the government shutdown on Q4. Sriram responded, "We did take the government shutdown into account as we set our Q4 guide, and that was the primary reason for the slight deceleration on a quarter-over-quarter basis."
* Tom DeBourcy, Nephron Research: Sought clarification on cost reductions. Sriram explained, "The cost reductions annualized is the full year impact of an action that you'll see in the 2026 time frame. What's realized in the quarter is true dollar savings that fell through within the quarter."

SENTIMENT ANALYSIS

* Analysts expressed concerns about macro environment pressures, competitive landscape, and size of orders, with a neutral to slightly negative tone as they pressed for details on integration, revenue guidance, and market stabilization.
* Management maintained a confident and disciplined tone in both prepared remarks and responses, emphasizing execution, integration progress, and prudent financial management. Toloue frequently highlighted being "ahead of schedule" and noted, "we're building a stronger, more agile and more scalable company."
* Compared to the previous quarter, management's confidence appeared slightly elevated, driven by progress on integration and synergy realization, while analysts' tone remained cautious but focused on clarity regarding guidance and market trends.

QUARTER-OVER-QUARTER COMPARISON

* Management reiterated revenue guidance and emphasized progress on integration and synergy targets versus the prior quarter, moving from 75% to $67 million realized of the $85 million synergy goal.
* Strategic focus shifted from acquisition closing and initial integration in Q2 to tangible cost synergies, combined portfolio momentum, and early commercial traction in Q3.
* Analysts continued to focus on integration execution, competitive dynamics, and market demand, with similar concerns as in the previous quarter.
* Key metrics changed, with Q3 revenue at $40.2 million compared to $24.5 million in Q2, and improved sequential instrument and Accelerator revenues noted.
* Management's tone was more assertive regarding integration progress, while maintaining caution in the face of ongoing market uncertainties.

RISKS AND CONCERNS

* Management cited continued weakness in U.S. academic and pharmaceutical end markets, smaller project and order sizes, and uncertainty due to the government shutdown.
* Sriram highlighted that "Q4 tends to be a tough quarter with all of the holidays... so we thought it prudent to hold the guide and reflect that impact."
* Analysts raised concerns about competition in high-sensitivity, high-multiplex platforms, and the durability of government and academic funding recovery.
* Management indicated that strategic investments are still intact and synergies are being realized to offset market headwinds.

FINAL TAKEAWAY

Quanterix delivered a quarter marked by strong execution on integration and synergy realization following the Akoya acquisition, maintained disciplined investment in growth areas including R&D and Alzheimer's diagnostics, and reinforced a commitment to end 2025 with approximately $120 million in cash and no debt. Management continues to see early commercial momentum, particularly in combined Simoa and Spatial portfolios, and expects to achieve cash flow breakeven in 2026 as integration milestones are completed and synergies are fully realized.

Read the full Earnings Call Transcript [https://seekingalpha.com/symbol/qtrx/earnings/transcripts]

MORE ON QUANTERIX

* Quanterix Corporation (QTRX) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4841597-quanterix-corporation-qtrx-q3-2025-earnings-call-transcript]
* Quanterix Corporation 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4841511-quanterix-corporation-2025-q3-results-earnings-call-presentation]
* Quanterix GAAP EPS of -$0.73 misses by $0.20, revenue of $40.23M beats by $2.39M [https://seekingalpha.com/news/4519581-quanterix-gaap-eps-of-0_73-misses-by-0_20-revenue-of-40_23m-beats-by-2_39m]
* Quanterix rises on CMS price for LucentAD Alzheimer blood biomarker test [https://seekingalpha.com/news/4493764-quanterix-rises-on-cms-price-for-lucentad-alzheimer-blood-biomarker-test]
* Seeking Alpha’s Quant Rating on Quanterix [https://seekingalpha.com/symbol/QTRX/ratings/quant-ratings]